What is Cofactor Genomics?
Cofactor Genomics is at the forefront of precision oncology, leveraging advanced RNA-Seq technology to develop predictive diagnostics. Their proprietary OncoPrism assay is designed to accurately forecast patient responses to immunotherapy, a critical advancement for personalized cancer care. The company is actively engaged in clinical trials across more than 24 healthcare systems, validating its multidimensional biomarker approach to better understand tumor responses and optimize treatment strategies for medical oncologists, pathologists, and clinical researchers focused on immune-oncology.
How much funding has Cofactor Genomics raised?
Cofactor Genomics has raised a total of $21.5M across 5 funding rounds:
Other Financing Round
$2.6M
Other Financing Round
$120K
Series A
$18M
Debt
$350K
Debt
$424K
Other Financing Round (2015): $2.6M with participation from Jude Gomila, Paul Buchheit, AME Cloud, David Lee, BioGenerator, 7percent Ventures, TenOneTen, and Data Collective
Other Financing Round (2015): $120K led by Y Combinator
Series A (2017): $18M supported by Menlo Ventures, Ascension Ventures, Stanford, Data Collective, Y Combinator, Wilson Sonsini Goodrich & Rosati, and iSelect Fund Management
Debt (2020): $350K featuring PPP
Debt (2021): $424K backed by PPP
Key Investors in Cofactor Genomics
Menlo Ventures
Menlo Ventures is a venture capital firm that invests in early and growth-stage technology companies, often taking board roles and partnering with founders through multiple stages of scale.
Ascension Ventures
Ascension Ventures is a strategic healthcare venture firm that invests in companies transforming the healthcare industry, backed by a network of leading community health systems.
Data Collective
Data Collective is a non-profit organization focused on building and supporting technology to help people find, understand, and share data, aiming to advance citizen knowledge and education.
What's next for Cofactor Genomics?
The substantial enterprise-level backing and recent strategic investment signal a strong growth phase for Cofactor Genomics. This influx of capital is likely to accelerate the expansion of their clinical trial network, further refine their OncoPrism assay, and potentially broaden their market reach. The company's focus on predictive diagnostics positions it to play a crucial role in the evolving landscape of precision medicine, aiming to enhance patient outcomes by matching them with the most effective treatments.
See full Cofactor Genomics company page
